ABG
CATX icon

Ally Bridge Group’s Perspective Therapeutics CATX Stock Holding History

Ally Bridge Group’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.86M Buy
+926,557
New +$3.91M 3.12% 16
2024
Q4 		– Sell
-341,739
Closed -$4.56M – 32
2024
Q3 		$4.56M Sell
341,739
-54,503
-14% -$725K 2.44% 22
2024
Q2 		$3.95M Buy
+396,242
New +$5.73M 2.35% 21

Other funds holding CATX

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ally Bridge Group's CATX Position: Q1 2026 in Review

Ally Bridge Group opened a new position in Perspective Therapeutics (CATX) in Q1 2026: 926,557 shares worth $3.86M. The stake represents 3.12% of the portfolio and ranks #16 among its holdings. This is a return to the name: Ally Bridge Group previously reported a position in CATX as recently as Q3 2024.

Ally Bridge Group first reported a position in CATX in Q2 2024 and has held it in 3 quarters since. The position peaked at $4.56M in Q3 2024. 138 funds tracked by Wall St. Rank hold CATX as of Q1 2026.

  • Ally Bridge Group held 926,557 shares of Perspective Therapeutics worth $3.86M as of Q1 2026.
  • Perspective Therapeutics was a new Ally Bridge Group position in Q1 2026.
  • Perspective Therapeutics made up 3.12% of Ally Bridge Group's portfolio in Q1 2026, its #16 holding.
  • Ally Bridge Group first reported a position in Perspective Therapeutics in Q2 2024 and has held it in 3 quarters since.
  • Ally Bridge Group's Perspective Therapeutics position peaked at $4.56M in Q3 2024.
  • 138 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q1 2026.

Based on Ally Bridge Group's 13F filing for Q1 2026, filed 18 May 2026.